128 related articles for article (PubMed ID: 15741517)
1. Experimental therapies hold promise for treating amyotrophic lateral sclerosis.
Friedrich MJ
JAMA; 2005 Mar; 293(9):1048-9. PubMed ID: 15741517
[No Abstract] [Full Text] [Related]
2. Amyotrophic lateral sclerosis and gene therapy.
Miller TM; Smith RA; Cleveland DW
Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
[No Abstract] [Full Text] [Related]
3. RNAi therapy: dominant disease gene gets silenced.
Xu Z; Xia XG
Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
[No Abstract] [Full Text] [Related]
4. RNA interference and amyotrophic lateral sclerosis.
Rizvanov AA; Gulluoglu S; Yalvaç ME; Palotás A; Islamov RR
Curr Drug Metab; 2011 Sep; 12(7):679-83. PubMed ID: 21740381
[TBL] [Abstract][Full Text] [Related]
5. Has gene therapy for ALS arrived?
Miller TM; Cleveland DW
Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
[No Abstract] [Full Text] [Related]
6. Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?
Aoki Y; Douglas AG; Wood MJ
Neurodegener Dis Manag; 2015; 5(2):93-5. PubMed ID: 25894871
[No Abstract] [Full Text] [Related]
7. [Gene therapy of ALS with short interfering RNA].
Yokota T
Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
[TBL] [Abstract][Full Text] [Related]
8. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
[TBL] [Abstract][Full Text] [Related]
9. RNA interference protects against ALS in mouse model.
Burton A
Lancet Neurol; 2005 May; 4(5):274-5. PubMed ID: 15861555
[No Abstract] [Full Text] [Related]
10. [Gene therapy of ALS with RNA interference].
Yokota T
Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
[TBL] [Abstract][Full Text] [Related]
11. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS.
Cleveland DW; Rothstein JD
Nat Rev Neurosci; 2001 Nov; 2(11):806-19. PubMed ID: 11715057
[No Abstract] [Full Text] [Related]
12. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis.
Miller TM; Kaspar BK; Kops GJ; Yamanaka K; Christian LJ; Gage FH; Cleveland DW
Ann Neurol; 2005 May; 57(5):773-6. PubMed ID: 15852369
[TBL] [Abstract][Full Text] [Related]
13. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.
Kaspar BK; Frost LM; Christian L; Umapathi P; Gage FH
Ann Neurol; 2005 May; 57(5):649-55. PubMed ID: 15852403
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia and Lou Gehrig.
Skene JP; Cleveland DW
Nat Genet; 2001 Jun; 28(2):107-8. PubMed ID: 11381249
[No Abstract] [Full Text] [Related]
15. [Autosomal dominant ALS].
Abe K
Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):320-2. PubMed ID: 10434663
[No Abstract] [Full Text] [Related]
16. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments.
Brown RH
Ann Neurol; 1996 Feb; 39(2):145-6. PubMed ID: 8967744
[No Abstract] [Full Text] [Related]
17. Genetic aspects of amyotrophic lateral sclerosis.
Siddique T; Lalani I
Adv Neurol; 2002; 88():21-32. PubMed ID: 11908227
[No Abstract] [Full Text] [Related]
18. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
Azzouz M; Ralph GS; Storkebaum E; Walmsley LE; Mitrophanous KA; Kingsman SM; Carmeliet P; Mazarakis ND
Nature; 2004 May; 429(6990):413-7. PubMed ID: 15164063
[TBL] [Abstract][Full Text] [Related]
19. Playng defense against Lou Gehrig's disease.
Aebischer P; Kato AC
Sci Am; 2007 Nov; 297(5):86-93. PubMed ID: 17990828
[No Abstract] [Full Text] [Related]
20. Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient.
Shook SJ; Pioro EP
Ann Neurol; 2009 Jan; 65 Suppl 1():S10-6. PubMed ID: 19191305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
